[
  {
    "title": "Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients",
    "url": "https://ejhp.bmj.com/content/27/e1/e41",
    "authors": "Luis Margusino-Framiñán, Purificación Cid-Silva, Sandra Rotea-Salvo, Álvaro Mena-de-Cea, Francisco Suárez-López, Pilar Vázquez-Rodríguez, Manuel Delgado-Blanco, Ana Isabel Sanclaudio-Luhia, Isabel Martín-Herranz, Ángeles Castro-Iglesias",
    "institution": "Pharmacy Service, Universitary Hospital of A Coruña, A Coruña, Spain. Division of Clinical Virology, Biomedical Research Institute of A Coruña (INIBIC), Universitary Hospital of A Coruña (CHUAC), Sergas, University of A Coruña (UDC), A Coruña, Spain. Infectious Diseases Unit. Internal Medicine Service, Universitary Hospital of A Coruña (CHUAC), A Coruña, Spain. Hepatology Unit, Digestive System Service, University Hospital of A Coruña (CHUAC), A Coruña, Spain. Information Systems Department, University Hospital of A Coruña, A Coruña, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2019-002060",
    "filters": {
      "actSubs": ["Sofosbuvir / Velpatasvir", "Ribavirin", "Glecaprevir / Pibrentasvir"],
      "indication": ["Hepatitis C Genotype 3", "Liver Fibrosis"],
      "statedClass": [],
      "studyDesign": ["Cohort (Prospective Observational Study)"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": ["51 - 100"],
      "numPrescriptions": [],
      "criteriaMethod": ["Fisher’s Exact Test", "Mann-Whitney U Test", "Real-Time Polymerase Chain Reaction"],
      "studyLength": ["1 year - 2 years"],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": ["safetyProfile"],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": ["compliance"]
    }
  },
  {
    "title": "Evaluation of the stability of vancomycin solutions at concentrations used in clinical services",
    "url": "https://ejhp.bmj.com/content/27/e1/e87",
    "authors": "Morgane Masse, Stéphanie Genay, Anthony Martin Mena, Natacha Carta, Damien Lannoy, Christine Barthélémy, Bertrand Décaudin, Pascal Odou",
    "institution": "Univ. Lille, CHU Lille, ULR 7365–GRITA–Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2019-002076",
    "filters": {
      "actSubs": ["Vancomycin hydrochloride"],
      "indication": [],
      "statedClass": [],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Laboratory"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["HPLC-DAD", "Mann-Whitney U Test"],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": []
    }
  },
  {
    "title": "Long-term stability of ready-to-use norepinephrine solution at 0.2 and 0.5 mg/mL",
    "url": "https://ejhp.bmj.com/content/27/e1/e93",
    "authors": "Sixtine Gilliot, Morgane Masse, Stéphanie Genay, Damien Lannoy, Christine Barthélémy, Bertrand Décaudin, Pascal Odou",
    "institution": "EA 7365–GRITA–Groupe de Recherche sur les formes Injectables et les Technologies Associées, University of Lille, CHU Lille, F-59000 Lille, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2019-002146",
    "filters": {
      "actSubs": ["Norepinephrine"],
      "indication": [],
      "statedClass": [],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Laboratory"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["Fast Reversed-Phase HPLC", "Cochran Test"],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": []
    }
  },
  {
    "title": "Cost efficacy analysis of abiraterone in newly diagnosed high risk metastatic castration sensitive prostate cancer",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A4.1",
    "authors": "A Soares, A Alcobia",
    "institution": "Hospital Garcia De Orta, Pharmacy Department, Almada, Portugal",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.8",
    "filters": {
      "actSubs": ["Abiraterone"],
      "indication": ["Prostate Cancer (Metastatic Castration Sensitive)"],
      "statedClass": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Portugal"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": ["clinicalTrials"],
      "youngPharma": [],
      "nextStep": [],
      "compliance": []
    }
  },
  {
    "title": "Application of a time slot model in oncology: delivery planning and process optimisation",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A8.2",
    "authors": "C Bertino, M Di Gerardo, A Pirrone, E Dalla Fontana, G Caravella, A Spagnuolo, R Cursano",
    "institution": "Università Degli Studi Di Milano, Scienze Farmaceutiche-Scuola Di Specializzazione Farmacia Ospedaliera, Milano, Italy. Asst Melegnano Martesana, Farmacia, Vizzolo Predabissi, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.18",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": ["pharmacoeconomy"],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": ["stock"],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": ["institutional"],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": []
    }
  },
  {
    "title": "Envisioning sustainability in personalised medicine: Fondo AIFA 5% and the Italian example",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A7.2",
    "authors": "F Bocchio, M Tizzoni, M Calvi, A Di Benedetto",
    "institution": "Fondazione Irccs Policlinico San Matteo Pavia, Uoc Farmacia, Pavia, Italy. Universita’ Degli Studi Di Milano, Scuola Di Specializzazione in Farmacia Ospedaliera, Pavia, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.16",
    "filters": {
      "actSubs": ["Venetoclax", "Eltrombopag", "Pembrolizumab", "Ruxolitinib", "Blinatumomab", "Trabectedina", "Cenegermin"],
      "indication": ["Leukaemia (Acute Myeloid)", "Lymphoma (Mantle Cell)", "Pure Red Cell Aplasia", "Lymphoma (Hodgkin)", "Lymphoma (non-Hodgkin)", "Myeloproliferative Neoplasm (BCR/JAK2-Rearranged)", "Leukaemia (Acute Lymphoblastic)", "Graft Versus Host Disease", "Ovarian Carcinoma", "Ovarian Serous Adenocarcinoma", "Neurotrophic Keratitis"],
      "statedClass": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": ["10 - 50"],
      "criteriaMethod": [],
      "studyLength": ["1 year - 2 years"],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": ["personalized"],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": ["selection"],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": ["policiesAudits"],
      "multidisciplinary": ["multidisciplinary"],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": []
    }
  },
  {
    "title": "Smartphone applications for patients diagnosed with genitourinary tumours: analysis of the quality using the mobile application rating scale",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A6.1",
    "authors": "MÁ Amor, R Collado-Borrell, V Escudero-Vilaplana, A Ribed-Sánchez, A Melgarejo-Ortuño, FJ García-Moreno, S García-Sánchez, Á Narrillos-Moraza, P Ruiz-Briones, A Herranz-Alonso, M Sanjurjo-Sáez",
    "institution": "Servicio De Farmacia, Hospital General Universitario Gregorio Marañón, Madrid, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.13",
    "filters": {
      "actSubs": [],
      "indication": ["Genitourinary Cancers", "Prostate Cancer", "Cervical Cancer", "Testicular Cancer", "Ovarian Carcinoma"],
      "statedClass": [],
      "studyDesign": ["Cross-Sectional Study"],
      "setting": [],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["MARS (Multivariate Adaptive Regression Splines)"],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": ["mobileVR"],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": []
    }
  },
  {
    "title": "Biological drugs for the treatment of moderate and severe plaque psoriasis: a cost analysis and an application of a correlation analysis to investigate cost effectiveness",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A1.2",
    "authors": "N Sagaria, D Mengato, I Corbucci, G Felluga, G Morandell, A Tavella",
    "institution": "School of Hospital Pharmacy, Department of Pharmaceutical Sciences University of Padova, Padova, Italy. Bolzano General Hospital, Hospital Pharmacy Department, Bolzano, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.2",
    "filters": {
      "actSubs": ["Adalimumab", "Infliximab", "Guselkumab"],
      "indication": ["Psoriasis (Moderate to Severe Plaque)"],
      "statedClass": ["Biosimilars"],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["Psoriasis Area and Severity Index (PASI)", "Correlation Analysis"],
      "studyLength": ["3 months - 5 months"],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": []
    }
  },
  {
    "title": "Economic comparison of therapeutic alternatives for firstline treatment of multiple myeloma",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A2.2",
    "authors": "MD Gil-Sierra, S Fenix-Caballero, MDP Briceño-Casado, M Dominguez-Cantero, EJ Alegre-Del Rey",
    "institution": "Hospital Universitario De Puerto Real, Pharmacy, Puerto Real, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.4",
    "filters": {
      "actSubs": ["Daratumumab", "Lenalidomide", "Bortezomib", "Thalidomide", "Melphalan", "Prednisone", "Dexamethasone"],
      "indication": ["Multiple Myeloma (Newly Diagnosed)"],
      "statedClass": [],
      "studyDesign": ["Systematic Review"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": ["clinicalTrials"],
      "youngPharma": [],
      "nextStep": [],
      "compliance": []
    }
  },
  {
    "title": "ABC-VEN crosstab analysis: a decision making system for anticancer medicines",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A2.3",
    "authors": "M Fragiadaki, E Rinaki, M Petrongonas, L Tzimis",
    "institution": "Chania General Hospital, Pharmacy, 73300-Chania, Greece",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.5",
    "filters": {
      "actSubs": ["Daratumumab", "Trastuzumab emtansine", "Pantoprazole"],
      "indication": [],
      "statedClass": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": ["Haematology", "Oncology", "Chemotherapy"],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["ABC/Pareto Analysis"],
      "studyLength": ["5 months - 1 year"],
      "country": ["Greece"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": ["stock"],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": []
    }
  },
  {
    "title": "Can rivaroxaban become cost saving compared with vitamin K antagonists in the treatment of patients with non-valvular atrial fibrillation in France?",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A1.1",
    "authors": "S Robert, F Vincent, S Vengadessane",
    "institution": "Chru Nancy, Pharmacy, Vandoeuvre Les Nancy, France. Hospices Civils De Lyon, Pharmacie, Lyon, France. Université Paris Descartes, Faculté De Pharmacie De Paris, Paris, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.1",
    "filters": {
      "actSubs": ["Rivaroxaban"],
      "indication": ["Nonvalvular Atrial Fibrillation"],
      "statedClass": ["Vitamin K Antagonists", "Novel Oral Anticoagulants"],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": []
    }
  },
  {
    "title": "Cost effectiveness analysis of patient self-administration of medication during hospitalisation in a cardiology unit",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A6.2",
    "authors": "CA Sørensen, A De Thurah, M Lisby, C Olesen, SB Sørensen, U Enemark",
    "institution": "Hospital Pharmacy Central Denmark Region, Clinical Pharmacy-Randers Regional Hospital, Randers Nø, Denmark. Randers Regional Hospital, Medical Department-Cardiology Unit, Randers Nø, Denmark. Aarhus University, Clinical Medicine, Aarhus, Denmark. Aarhus University Hospital, Rheumatology, Aarhus, Denmark. Aarhus University Hospital, Research Centre of Emergency Medicine, Aarhus, Denmark. Hospital Pharmacy Central Denmark Region, Clinical Pharmacy-Aarhus University Hospital, Aarhus, Denmark. Aarhus University, Public Health, Aarhus, Denmark",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.14",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": ["Cardiology"],
      "numPatients": ["101 - 500"],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Denmark"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": ["selfMedication"],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": ["errors"],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": []
    }
  },
  {
    "title": "Evaluation of bispectral index monitoring in general anaesthesia through a health technology assessment method: a possible introduction in clinical practice in an Italian hospital?",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A7.1",
    "authors": "E Guido, ME Borghesi, A Saccardi",
    "institution": "University of Milan, Specialisation School in Hospital Pharmacy, Milan, Italy. Asst Carlo Poma-Mantova, Hospital Pharmacy, Mantova, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.15",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "studyDesign": ["Systematic Review"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": ["preopMedication"],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": []
    }
  },
  {
    "title": "National reporting system for drug shortages: classification and trends in reported causes from 2015 to 2018",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A5.2",
    "authors": "A Benhabib, P Maison",
    "institution": "French National Agency for Medicines and Health Products Safety, Health Products Survey, Saint-Denis, France. Strasbourg Faculty of Pharmacy, Hospital Pharmacy, Strasbourg, France. Ea 7379- Paris Est Creteil University Upec and Chic Hospital, Epidemiology Department, Créteil, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.12",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": ["stock"],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": ["policiesAudits"],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": []
    }
  },
  {
    "title": "Study of the use of intravenous immunoglobulins during the fourth quarter of 2018 and analysis of its off-label use",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A2.1",
    "authors": "S Izquierdo Muñoz, A Pariente Junquera, A De Frutos Soto",
    "institution": "Hospital Clínico Universitario De Valladolid, Farmacia Hospitalaria, Valladolid, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.3",
    "filters": {
      "actSubs": [],
      "indication": ["Demyelinating Neuropathies", "Myasthenia Gravis", "Myopathy", "Encephalitis", "Encephalomyelitis", "Morvan Syndrome", "Paraneoplastic Syndrome", "Refractory Atopic Dermatitis", "Paraneoplastic Dermatomyositis", "Scleroderma", "Antisynthetase Syndrome"],
      "statedClass": ["Intravenous Immunoglobulins (IVIg)"],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": ["51 - 100"],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": ["offLabel"],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": []
    }
  },
  {
    "title": "Effectiveness evaluation of high cost drugs for advanced non-small-cell lung cancer: real world evidence, compliance with clinical practice guidelines and economic evaluation",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A3.1",
    "authors": "A Isoardo, E Grande, MM Ferrero, C Fruttero",
    "institution": "Ao S Croce E Carle, SC Farmacia Ospedaliera, Cuneo, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.6",
    "filters": {
      "actSubs": ["Pemetrexed", "Erlotinib", "Gefitinib", "Afatinib", "Osimertinib", "Crizotinib", "Pembrolizumab", "Nivolumab"],
      "indication": ["Advanced Non-Small Cell Lung Cancer"],
      "statedClass": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": ["51 - 100"],
      "numPrescriptions": [],
      "criteriaMethod": ["Kaplan-Meier Method"],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": ["compliance"]
    }
  },
  {
    "title": "New cancer drug approvals in Portugal",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A3.2",
    "authors": "A Alcobia, A Soares",
    "institution": "Hospital Garcia De Orta, Pharmacy Department, Almada, Portugal",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.7",
    "filters": {
      "actSubs": ["Midostaurin", "Olaparib", "Brentuksimab vedotin", "Vedotin", "Pomalidomide", "Durvalumab", "Venetoclax", "Ixazomib", "Alectinib", "Atezolizumab", "Cabozantinib"],
      "indication": ["Refractory Cancer", "Metastatic Cancer"],
      "statedClass": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Portugal"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": ["policiesAudits"],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": []
    }
  },
  {
    "title": "Budget impact analysis of a natalizumab extended interval dosing regimen",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A4.2",
    "authors": "E Pierobon, A Mastrogiacomo, F Capano, D Ielo",
    "institution": "AOU San Luigi Gonzaga, Pharmacy, Turin, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.9",
    "filters": {
      "actSubs": ["Natalizumab"],
      "indication": ["Progressive Multifocal Leukoencephalopathy", "Multiple Sclerosis"],
      "statedClass": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": ["501 - 1000"],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": []
    }
  },
  {
    "title": "Introduction of rituximab biosimilar: an opportunity to improve health system efficiency?",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A4.3",
    "authors": "C Panciroli, L Cervi, D Mazza, G Mangoni, M Dall’aglio, F Ruggiero, ML Medaglia",
    "institution": "Asst Grande Ospedale Metropolitano Niguarda, SC Farmacia, Milan, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.10",
    "filters": {
      "actSubs": ["Rituximab"],
      "indication": [],
      "statedClass": ["Biosimilars"],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": ["More than 1000"],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": ["switching"],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": ["vigilance"],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": ["safetyProfile"],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": ["selection"],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": ["adverseEvents"],
      "adherence": ["adherence"],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": ["clinicalTrials"],
      "youngPharma": [],
      "nextStep": [],
      "compliance": []
    }
  },
  {
    "title": "Assessment of asthma diagnosed population eligible for new monoclonal antibody therapy and related cost in the Veneto region",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A5.1",
    "authors": "L Degli Esposti, V Perrone, D Sangiorgi, AM Menti, M Andretta",
    "institution": "Clicon SRL-Health-Economics and Outcomes Research, Clicon SRL-Health-Economics and Outcomes Research, Ravenna, Italy. Uoc Hta-Azienda Zero-Regione Veneto, Uoc Hta-Azienda Zero-Regione Veneto, Padova, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.11",
    "filters": {
      "actSubs": ["Theophylline"],
      "indication": ["Asthma (Severe Refractory)"],
      "statedClass": ["Monoclonal Antibodies", "Inhaled Corticosteroids", "Long-Acting β Adrenoceptor Agonists", "Antileukotriene Agents", "Anticholinergics", "Systemic Corticosteroids"],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": ["More than 1000"],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": []
    }
  },
  {
    "title": "Impact of supply problems in a hospital pharmacy service",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A8.1",
    "authors": "B Zarate, Á Pieras López, R Menárguez Blanc, A Iglesias Carbajo, C Álvarez Asteinza, A Lozano Blazquez, Á Arias-Martinez, I Maray Mateos, MD Macía Rivas, CL Fernández Laguna",
    "institution": "Hospital Universitario Central De Asturias, Pharmacy, Oviedo, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.17",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "studyDesign": ["Cohort (Prospective Observational Study)"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": ["3 months - 5 months"],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": ["stock"],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": []
    }
  },
  {
    "title": "Hospital pharmacists aged <45 years: an employment status and job satisfaction survey in Italy",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A9.1",
    "authors": "SE Campbell Davies, G Bagaglini, F Brera",
    "institution": "Italian Society of Hospital Pharmacy Sifo, Young Pharmacists, Milano, Italy. Italian Society of Hospital Pharmacy Sifo, Young Pharmacists, Roma, Italy. Italian Society of Hospital Pharmacy Sifo, Young Pharmacists, San Donà Di Piave, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.19",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "studyDesign": ["Cross-Sectional Study"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": ["Less than 3 months"],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": ["policiesAudits"],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": ["youngPharma"],
      "nextStep": [],
      "compliance": []
    }
  },
  {
    "title": "Implementation of home delivery and telepharmacy systems in a third level hospital",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A9.2",
    "authors": "J Cordero-Ramos, Ú Baños-Roldán, JA Fernandez-González-Caballos, C Castillo-Martin, EM Delgado-Cuesta",
    "institution": "Hospital Universitario Virgen Macarena, Hospital Pharmacy, Seville, Spain. Hospital Universitario Virgen Macarena, Primary Care Pharmacy Department, Seville, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.20",
    "filters": {
      "actSubs": [],
      "indication": ["Multiple Sclerosis"],
      "statedClass": [],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": ["101 - 500"],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": ["outpatient"],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": ["adverseEvents"],
      "adherence": ["adherence"],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": []
    }
  },
  {
    "title": "Improvement in an antimicrobial stewardship programme after implementing a screening alert system",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A10.1",
    "authors": "E Tevar, MJ Castillo Méndez, A Ferrer Machín, ML Padilla Salazar, L Abella Vázquez, J Ode Febles, K Álvarez Tosco, M Hayek Peraza, MÁ Ocaña Gómez, J Merino Alonso",
    "institution": "Hospital Nuestra Señora De La Candelaria, Pharmacy Service, Santa Cruz De Tenerife, Spain. Hospital Nuestra Señora De La Candelaria, Computer Department, Santa Cruz De Tenerife, Spain. Hospital Nuestra Señora De La Candelaria, Internal Medicine, Santa Cruz De Tenerife, Spain. Hospital Nuestra Señora De La Candelaria, Microbiology Service, Santa Cruz De Tenerife, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.21",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "studyDesign": ["Quasi-Experimental Design"],
      "setting": ["Hospital"],
      "ward": ["Cardiology", "Vascular Surgery", "General Surgery", "Geriatrics", "Internal Medicine", "Neurology", "Traumatology"],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": ["softwareAided"],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": ["stewardship"],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": []
    }
  },
  {
    "title": "Economic impact of the introduction of lamivudine plus dolutegravir bitherapy in HIV naive patients",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A10.2",
    "authors": "L Cantarelli, J Gonzalez Garcia, B Del Rosario Garcia, J Ramos Rodriguez, F Gutierrez Nicolas, J Garcia Cairos, S Garcia Gil, GJ Nazco Casariego",
    "institution": "Complejo Hospitalario Universitario De Canarias, Pharmacy, Santa Cruz De Tenerife, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.22",
    "filters": {
      "actSubs": ["Dolutegravir", "Abacavir", "Lamivudine", "Emtricitabine", "Tenofovir", "Raltegravir"],
      "indication": ["HIV (Treatment-Naive)"],
      "statedClass": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": []
    }
  },
  {
    "title": "Efficiency of precision dosing with intravenous immunoglobulins in patients with haematological malignancies",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A11.1",
    "authors": "M Dominguez Cantero, FJ Salmeron-Navas, EM Barreiro-Fernandez, C Moreno-Ramos, MP Briceño-Casado",
    "institution": "Hospital Universitario Puerto Real, Servicio De Farmacia, Cadiz, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.23",
    "filters": {
      "actSubs": ["Intravenous Immunoglobulin (IVIg)"],
      "indication": ["Hematologic Malignancy", "Immunodeficiency", "Autoimmune Hemolytic Anemia", "Idiopathic Thrombocytopenic Purpura"],
      "statedClass": [],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": []
    }
  }
]